# KORU Medical Systems, Inc.: Form 10-Q for the period ended Jun 30, 2026

- Company: [KORU Medical Systems, Inc.](/companies/krmd.md) (CIK 704440)
- Form: 10-Q
- Filed: 2026-08-05
- Accepted by EDGAR: Aug 5, 2026, 20:08 ET
- Period: 2026-06-30
- Accession: 0001161697-26-000189
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/704440/000116169726000189/form_10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/704440/000116169726000189/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2026-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2026-04-01 to 2026-06-30 | $12.0m | us-gaap:Revenues |
| Revenue | 6 months, 2026-01-01 to 2026-06-30 | $23.8m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2026-04-01 to 2026-06-30 | $4.2m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2026-01-01 to 2026-06-30 | $8.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2026-04-01 to 2026-06-30 | $7.8m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2026-01-01 to 2026-06-30 | $15.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2026-04-01 to 2026-06-30 | $1.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2026-01-01 to 2026-06-30 | $2.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2026-04-01 to 2026-06-30 | $5.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2026-01-01 to 2026-06-30 | $12.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2026-04-01 to 2026-06-30 | $627.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2026-01-01 to 2026-06-30 | −$237.9k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2026-04-01 to 2026-06-30 | $5.8k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2026-01-01 to 2026-06-30 | $5.8k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2026-04-01 to 2026-06-30 | $252.4k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2026-01-01 to 2026-06-30 | −$554.6k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2026-04-01 to 2026-06-30 | $0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2026-01-01 to 2026-06-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2026-04-01 to 2026-06-30 | $0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2026-01-01 to 2026-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2026-04-01 to 2026-06-30 | 49,509,437 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2026-01-01 to 2026-06-30 | 46,223,623 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2026-01-01 to 2026-06-30 | $230.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2026-01-01 to 2026-06-30 | $154.1k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2026-06-30 | $8.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2026-06-30 | $19.5m | us-gaap:AssetsCurrent |
| Total assets | at 2026-06-30 | $28.0m | us-gaap:Assets |
| Current liabilities | at 2026-06-30 | $7.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2026-06-30 | $9.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2026-06-30 | $18.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 2,249 characters.

On May 18, 2026, the Company purchased certain contracts and intellectual property assets from a third-party in exchange for a combination of cash and 125,628 shares of the Company’s common stock, par value $0.01 per share, which shares represented $500,000 of the aggregate purchase price for the assets. The shares were issued to the collateral agent on behalf of the seller’s noteholders, and are subject to an 18-month restriction on transfer. The Company relied on Rule 506 of Regulation D under the Securities Act of 1933, as amended, in connection with the issuance.

\- 20 -

### PART II – ITEM 6. EXHIBITS.

| Exhibit No. | Description |
| --- | --- |
| 31.1 | Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002 |
| 31.2 | Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002 |
| 32.1 | Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002 |
| 32.2 | Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002 |
| 101.INS | Inline XBRL Instance Document - the XBRL Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF | Inline XBRL Taxonomy Definition Linkbase Document |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

\- 21 -

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

|  |  |
| --- | --- |
|  | KORU MEDICAL SYSTEMS, INC. |
| August 5, 2026 | /s/ Adam Kalbermatten |
|  | Adam Kalbermatten, Chief Executive Officer (Principal Executive Officer) |
| August 5, 2026 | /s/ Thomas Adams |
|  | Thomas Adams, Chief Financial Officer and Treasurer (Principal Financial Officer) |

\- 22 -

## Controls and procedures

As filed, 1,345 characters.

The Company’s management, including the Company’s Principal Executive Officer and Principal Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the three months ended June 30, 2026, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

## Risk factors

As filed, 359 characters.

Our operations and financial results are subject to various risks and uncertainties, including those described in “PART 1, ITEM 1A. RISK FACTORS” in our Annual Report on Form 10-K for the year ended December 31, 2025, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock.

Filed Aug 5, 2026.
Source: SEC EDGAR, the filing index for accession 0001161697-26-000189. Last ingested by Listed: Oct 24, 2026, 14:56 ET. No prices; not investment advice.